MD-224 is a novel PROTAC-based small molecule designed to specifically degrade the MDM2 proto-oncogene. As a pioneering and highly effective degrader, MD-224 represents a new class of anticancer agents with significant potential in targeted therapy. Functioning as a click chemistry reagent, it harbors an alkyne group, enabling it to engage in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules featuring Azide groups.
Usually ships within 24 hours.